TOMI Establishes Singapore Base to Address Significant Growth Opportunities in Asia

BEVERLY HILLS, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (OTCQB:TOMZ) (TOMI), a global bacteria decontamination and infection prevention company, announced it has signed a distribution agreement with TOMI ASIA Pte Ltd. (TOMI Asia), a Limited Singapore Company. TOMI Asia will serve multiple markets in Asia, providing local distribution, warehousing, sales, training, services and support for TOMI’s suite of products. Under the terms of the agreement, TOMI Asia will have exclusive rights to market TOMI’s brand and products in healthcare and hospitality verticals including, but not limited to, hospitals, outpatient clinics, ambulatory care, oral surgery centers, dental offices, surgical centers, medical facilities, nursing homes, walk-in clinics, public transportation and childcare centers.

Dr. Halden Shane, TOMI’s Chief Executive Officer, stated: “We are excited to establish an Asian-based center from which to further expand our footprint in the region. Since the beginning of 2015, TOMI SteraMist™ has quickly established a reputation for its effectiveness in a variety of applications throughout the world, and we have built strong relationships with distributors, independent contractors, and strategic partners to support our continued growth. This agreement enhances our existing Singapore distribution partnership with SG Environmental Solutions and validates the increasing demand for infection control and decontamination products in Asia.  In addition, TOMI Asia provides us with a logistical and service advantage that enables us to more quickly and effectively meet the needs of our customers.”

About TOMI^™ Environmental Solutions, Inc.
TOMI^™ Environmental Solutions, Inc. (OTCQB:TOMZ) is a global bacteria decontamination and infectious disease control company, providing eco-friendly environmental solutions for indoor surface decontamination through manufacturing, sales and licensing of our premier platform of Hydrogen Peroxide based products that uses Binary Ionization Technology^® (BIT^™) , a state of the art technology for the production of its six-log mist represented by the TOMI™ SteraMist™ brand.

TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality Association, and The International Ozone Association. For additional product information, visit www.tomiesinc.com or contact us at info@tomiesinc.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.